Large-scale testing (Phase 3)UnknownNCT01352091What this trial is testingAdjuvant AI Combined With ZoladexWho this might be right forBreast Cancer Fudan University 670
Testing effectiveness (Phase 2)UnknownNCT01266213What this trial is testingFulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal WomenWho this might be right forMetastatic Breast CancerEstrogen Receptor Positive TumorBreast Cancer Nos Premenopausal Samsung Medical Center 147
Large-scale testing (Phase 3)Study completedNCT00390455What this trial is testingFulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-PositiveWho this might be right forEstrogen Receptor PositiveHER2 Positive Breast CarcinomaHER2/Neu Negative+5 more National Cancer Institute (NCI) 295
Testing effectiveness (Phase 2)UnknownNCT04318223What this trial is testingPalbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal TherapyWho this might be right forMetastatic Breast CancerLocally Advanced Breast Cancer Consorzio Oncotech 168
Early research (Phase 1)Study completedNCT01969643What this trial is testingA Safety Study of SGN-LIV1A in Breast Cancer PatientsWho this might be right forHER2 Positive Breast NeoplasmsHormone Receptor Positive Breast NeoplasmsTriple Negative Breast Neoplasms+1 more Seagen Inc. 290
Testing effectiveness (Phase 2)UnknownNCT04034589What this trial is testingPyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast CancerWho this might be right forMetastatic Breast Cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 46
Early research (Phase 1)Looking for participantsNCT07524322What this trial is testingStudy of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid TumorsWho this might be right forBreast CancerOvarian CancerEndometrial Cancer+6 more Regor Pharmaceuticals Inc. 63
Testing effectiveness (Phase 2)Study completedNCT03007979What this trial is testingAlternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast CancerWho this might be right forBreast CancerBreast CarcinomaCancer of Breast+1 more Washington University School of Medicine 55
Not applicableStudy completedNCT01617954What this trial is testingPRospective Study Of MammaPrint in Patients With an Intermediate Recurrence ScoreWho this might be right forHormone Receptor Positive Malignant Neoplasm of Breast Agendia 820
Not applicableEnded earlyNCT02149173What this trial is testingF-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted TherapyWho this might be right forEstrogen Receptor PositiveRecurrent Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7 University of Washington 29
Large-scale testing (Phase 3)Ended earlyNCT06038539What this trial is testingEfficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast CancerWho this might be right forHR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Biocon Biologics UK Ltd 55
Not applicableUnknownNCT04891731What this trial is testingEfficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast CancerWho this might be right forHormone Receptor-positive Breast Cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 120
Testing effectiveness (Phase 2)Looking for participantsNCT07340541What this trial is testingEvolutionary Clinical Trial for Novel Biomarker-Driven TherapiesWho this might be right forBreast CancerMetastatic Breast CancerTriple Negative Breast Cancer+2 more UNC Lineberger Comprehensive Cancer Center 700
Testing effectiveness (Phase 2)Ended earlyNCT02395627What this trial is testingReversing Therapy Resistance With Epigenetic-Immune ModificationWho this might be right forBreast Neoplasms University of California, San Francisco 38
Testing effectiveness (Phase 2)Looking for participantsNCT07396324What this trial is testingNeoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast CancerWho this might be right forHR-positive/HER2-negative Breast Cancer RenJi Hospital 55
Not applicableUnknownNCT05814224What this trial is testingMonitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNAWho this might be right forHormone Receptor Positive Breast CarcinomaBreast NeoplasmsNeoplasms, Breast+4 more Centro di Riferimento Oncologico - Aviano 164
Testing effectiveness (Phase 2)Study completedNCT02229136What this trial is testingMiracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by EverolimusWho this might be right forStomatitisOral MucositisNeoplasm of the Breast+1 more US Oncology Research 104
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944434What this trial is testingFACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast CancerWho this might be right forBreast Cancer Fondazione Sandro Pitigliani 116
Very early researchWithdrawnNCT04088032What this trial is testingNeoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast CancerWho this might be right forBreast Cancer FemaleLocally Advanced Breast CancerHormone Receptor Positive Malignant Neoplasm of Breast Alison Stopeck
Post-approval studies (Phase 4)WithdrawnNCT03988114What this trial is testingAbemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast CancerWho this might be right forMetastatic Breast Cancer Eli Lilly and Company